Elisa Oricchio

US Patent:

20140079698, Mar 20, 2014

Filed:

Apr 6, 2012

Appl. No.:

14/009833

Inventors:

Hans-Guido Wendel - New York City NY, US
Elisa Oricchio - New York City NY, US

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER - NEW YORK NY

International Classification:

C07K 16/28
C07K 14/705

US Classification:

4241341, 5303873, 4353201, 435 611, 435 614

Abstract:

The present invention is directed to methods and compositions for treating cancer, including, hematologic malignancies, such as B-cell malignancies, with anti-tumor antibody-tumor suppressor fusion proteins in order to selectively restore tumor suppressor gene function to cancer cells in which such tumor suppressor gene function has been lost. The present invention is also directed to methods and compositions for diagnosing cancer and for predicting and assessing response to treatment.

US Patent:

20140080838, Mar 20, 2014

Filed:

Mar 14, 2013

Appl. No.:

13/826056

Inventors:

Elisa Oricchio - New York NY, US

Assignee:

Memorial Sloan-Kettering Cancer Center - New York NY

International Classification:

A61K 31/519
G01N 33/68
C12Q 1/68
A61K 31/495

US Classification:

51425216, 436501, 435 792, 506 9, 435 612, 435 611, 435 74, 435 723

Abstract:

The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB.

US Patent:

20130064810, Mar 14, 2013

Filed:

Feb 28, 2011

Appl. No.:

13/581032

Inventors:

Hans-Guido Wendel - New York NY, US
Andrew L. Wolfe - New York NY, US
Konstantinos John Mavrakis - New York NY, US
Elisa Oricchio - New York NY, US
Adolfo A. Ferrando - New York NY, US
Kim De Keersmaecker - Leuven, BE
Teresa Palomero - New York NY, US
Franki Speleman - Ghent, BE
Pieter Van Vlierberghe - Ghent, BE

International Classification:

A61K 31/7088
A61P 35/00
C07H 21/02
A61K 39/395
C12Q 1/68
C12N 5/09

US Classification:

4241301, 435 613, 435 612, 435375, 536 245, 514 44 A

Abstract:

The present invention relates to microRNAs (miRNAs) which are associated with cancer, particularly including hematologic malignancies, and particularly T-cell acute lymphoblastic leukemia (T-ALL), and to the assessment and modulation thereof in the treatment and management of cancer. The present invention is directed to methods and compositions for diagnosing and treating cancer, particularly T-ALL, by modulating miRNAs, and the use of miRNAs and antagonists thereof, particularly antagomirs, for predicting and assessing response to treatment, in assays for isolating and selecting antagists, and as compositions for the treatment and management of cancer. Methods and compositions are provided for treatment or alleviation of cancer, particularly T-ALL, with antagonists/antagomirs of miRNAs, particularly one or more of miR-19b, miR-20a, miR26, miR92, miR148 and miR223.

US Patent:

20160331750, Nov 17, 2016

Filed:

Jan 7, 2016

Appl. No.:

14/990577

Inventors:

- New York NY, US
Elisa Oricchio - New York NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

A61K 31/519
C12Q 1/68
G01N 33/574
A61K 31/404

Abstract:

The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB.